Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9-PAMI: Early PCSK9 inhibitor before PPCI in acute myocardial infarction
ChiCTR2000035056Phase 4Recruiting
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of evolocumab and alirocumab in myocardial infarction (MI) (2 arms), sponsored by Zhongda Hospital, Southeast University. Primary endpoint: Major cardiovascular adverse events. Started Jul 2020; status: recruiting.
02
Drugs
evolocumabalirocumab
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2000035056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035056.